TY -的T1 -没有利用Aβ42 <子> < /订阅>降低非甾体抗炎药对预防老年痴呆症在六个池队列研究摩根富林明-神经学乔-神经病学SP - 2291 LP - 2298——10.1212/01. wnl.0000313933.17796。首页f6六世- 70 - 24 AU - c a Szekely AU - r . c .绿盟J.C.S. Breitner AU - t .Østbye盟- a s Beiser AU - m . m . Corrada AU - h·h·道奇盟Ganguli m . AU - c·h·川AU - l·h·库盟b . m . Psaty AU - s·m·雷斯尼克盟p . a .狼盟——a . b . Zonderman盟——p·p·k . a Welsh-Bohmer盟Zandi Y1 - 2008/06/10 UR - //www.ez-admanager.com/content/70/24/2291.abstract N2 -简介:观测研究表明降低老年痴呆症的发病率(首页广告)的用户非甾体类抗炎药(非甾体抗炎药)。一种假说认为,非甾体抗炎药的子集被称为选择性Aβ42-lowering代理(萨拉斯)负责这个明显减少广告风险。方法:我们集中个体层面的数据从六个前瞻性研究来获得足够的样本来检查广告的用户风险萨拉vs non-SALA非甾体类抗炎药。结果:13499年最初dementia-free参与者(70863组),820年开发的广告。非甾体抗炎药(29.6%)的用户显示降低广告的风险(风险比调整(aHR) 0.77, 95% CI 0.65 - -0.91)。萨拉斯的点估计相似(aHR 0.87,可信区间0.72 - -1.04)和non-SALAs (aHR 0.75,可信区间0.56 - -1.01)。因为573服用非甾体消炎药(14.5%)报道萨拉和non-SALA,我们检查了他们的使用单独和组合。结果明显是0.82只是因为萨拉(CI 0.67 - -0.99), 0.60 (non-SALA可信区间0.40 - -0.90),和0.87 (CI 0.57 - -1.33)为非甾体抗炎药(瓦尔德测试差异,p = 0.32)。40.7%的参与者使用阿司匹林还显示减少广告的风险,即使他们没有使用其他非甾体抗炎药(aHR 0.78,可信区间0.66 - -0.92)。 By contrast, there was no association with use of acetaminophen (aHR 0.93, CI 0.76–1.13). Conclusions: In this pooled dataset, nonsteroidal anti-inflammatory drug (NSAID) use reduced the risk of Alzheimer dementia (AD). However, there was no apparent advantage in AD risk reduction for the subset of NSAIDs shown to selectively lower Aβ42, suggesting that all conventional NSAIDs including aspirin have a similar protective effect in humans. AD=Alzheimer dementia; aHR=adjusted hazard ratio; BLSA=Baltimore Longitudinal Study of Aging; CCS=Cache County Study; CHS=Cardiovascular Health Study; COX=cyclooxygenases; CSHA=Canadian Study of Health and Aging; FHS=Framingham Heart Study; IRB=institutional review board; MoVIES=Monongahela Valley Independent Elders Study; NSAID=nonsteroidal anti-inflammatory drug; OTC=over-the-counter; SALA=selective Aβ42-lowering agent. ER -